a deal in mid-March in which Pfizer leveraged the German biotech's drug development platform and both companies utilized each other's research and development sites. The duo's vaccine for the novel coronavirus could be set for emergency use in the fall — well ahead of experts' predictions — with the potential for hundreds of millions of doses to be produced in 2021.
As biotechs showcase their ability to quickly develop novel vaccines, we expect to see pharmaceutical companies increasingly forge partnerships with them that could outlast the pandemic. The promise of BioNTech's recent work with Pfizer lies in biotech firms' research brawn and ability to develop vaccine candidates for novel diseases via technologies like AI.
Could businesses try to financially benefit from the new vaccine? jmyers42 lccc141
Watch out people! A ‘fast track’ vaccine may not be efficient & safe if done with $$$ in mind, instead of science and due procedure/time for vaccines
about time
Who are the guinea pigs going to be?
Just give it now
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: BusinessInsider - 🏆 729. / 51 اقرأ أكثر »
مصدر: BusinessInsider - 🏆 729. / 51 اقرأ أكثر »
مصدر: BusinessInsider - 🏆 729. / 51 اقرأ أكثر »